BidaskClub cut shares of Abbott Laboratories (NYSE:ABT) from a buy rating to a hold rating in a research note released on Sunday.

A number of other research firms have also recently weighed in on ABT. Stifel Nicolaus reiterated a buy rating and set a $58.00 price target on shares of Abbott Laboratories in a report on Friday, July 21st. Barclays PLC reiterated an overweight rating and set a $57.00 price target (up from $52.00) on shares of Abbott Laboratories in a report on Saturday, July 22nd. Jefferies Group LLC reiterated a buy rating and set a $58.00 price target on shares of Abbott Laboratories in a report on Thursday. Zacks Investment Research cut Abbott Laboratories from a buy rating to a hold rating in a report on Wednesday, August 2nd. Finally, BTIG Research began coverage on Abbott Laboratories in a report on Wednesday, June 21st. They set a buy rating and a $56.00 price target for the company. Six investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $51.93.

Shares of Abbott Laboratories (NYSE ABT) traded up 0.06% during midday trading on Friday, reaching $49.29. 2,293,818 shares of the company traded hands. Abbott Laboratories has a 1-year low of $37.38 and a 1-year high of $51.13. The firm has a market capitalization of $85.53 billion, a PE ratio of 69.03 and a beta of 1.07. The stock has a 50 day moving average price of $48.97 and a 200 day moving average price of $45.28.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. The business had revenue of $6.64 billion during the quarter, compared to analysts’ expectations of $6.63 billion. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The company’s revenue was up 24.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.55 EPS. Analysts expect that Abbott Laboratories will post $2.49 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally published by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/07/abbott-laboratories-nyseabt-lowered-to-hold-at-bidaskclub.html.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, August 15th. Stockholders of record on Friday, July 14th will be paid a $0.265 dividend. This represents a $1.06 annualized dividend and a dividend yield of 2.15%. The ex-dividend date of this dividend is Wednesday, July 12th. Abbott Laboratories’s payout ratio is presently 149.30%.

In other news, insider Brian J. Blaser sold 15,000 shares of Abbott Laboratories stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $50.00, for a total value of $750,000.00. Following the completion of the transaction, the insider now owns 143,154 shares in the company, valued at approximately $7,157,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jared Watkin sold 552 shares of Abbott Laboratories stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $47.97, for a total value of $26,479.44. Following the completion of the transaction, the insider now owns 47,090 shares of the company’s stock, valued at approximately $2,258,907.30. The disclosure for this sale can be found here. Insiders sold a total of 218,702 shares of company stock valued at $10,149,733 in the last quarter. Company insiders own 0.76% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Burt Wealth Advisors boosted its position in shares of Abbott Laboratories by 14.4% in the second quarter. Burt Wealth Advisors now owns 3,181 shares of the healthcare product maker’s stock valued at $154,000 after buying an additional 400 shares during the last quarter. TRUE Private Wealth Advisors bought a new position in shares of Abbott Laboratories during the second quarter valued at about $218,000. Fagan Associates Inc. bought a new position in shares of Abbott Laboratories during the second quarter valued at about $335,000. Venturi Wealth Management LLC bought a new position in shares of Abbott Laboratories during the second quarter valued at about $520,000. Finally, Meiji Yasuda Asset Management Co Ltd. boosted its position in shares of Abbott Laboratories by 7.3% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 119,435 shares of the healthcare product maker’s stock valued at $5,806,000 after buying an additional 8,080 shares during the last quarter. Institutional investors and hedge funds own 70.98% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Analyst Recommendations for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.